Skip to main content
Erschienen in: Reactions Weekly 1/2022

01.10.2022 | Clinical study

mRNA COVID-19 vaccine safety in recipients aged 12 to 64 years

Erschienen in: Reactions Weekly | Ausgabe 1/2022

Einloggen, um Zugang zu erhalten

Excerpt

Safety surveillance in the US identified signals for anaphylaxis, and myocarditis or pericarditis, after mRNA COVID-19 vaccination in recipients 12 to 64 years of age, say authors of a study published in Vaccine.
Metadaten
Titel
mRNA COVID-19 vaccine safety in recipients aged 12 to 64 years
Publikationsdatum
01.10.2022
Verlag
Springer International Publishing
Erschienen in
Reactions Weekly / Ausgabe 1/2022
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI
https://doi.org/10.1007/s40278-022-25276-9

Weitere Artikel der Ausgabe 1/2022

Reactions Weekly 1/2022 Zur Ausgabe

Case report

Docetaxel

Case report

Multiple drugs

Case report

Crizotinib